World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT02683863
Date of registration: 14/01/2016
Prospective Registration: No
Primary sponsor: Multiple Sclerosis Center of Northeastern New York
Public title: Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Scientific title: An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis
Date of first enrolment: August 2015
Target sample size: 20
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02683863
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 4
Countries of recruitment
United States
Contacts
Name:     Keith Edwards, M.D
Address: 
Telephone:
Email:
Affiliation:  MS Center of Northeastern NY
Key inclusion & exclusion criteria

Inclusion Criteria (MS Population):

To be eligible to participate in this study, candidates must meet the following eligibility
criteria at screening, or at the timepoint specified in the individual eligibility
criterion listed:

1. Ability to understand the purpose and risks of the study and provide signed and dated
informed consent and authorization to use protected health information (PHI) in
accordance with national and local patient privacy regulations. Subjects must provide
separate informed consent to participate in this CSF study.

2. Aged 25 to 65 years-old, inclusive, at the time of informed consent.

3. Male of female subject with a confirmed diagnosis of SPMS.

4. EDSS score between 3 and 7, inclusive, at screening.

5. Weight should be between 130 and 200 lb.

Exclusion Criteria (MS Population)

- Candidates will be excluded from study entry if any of the following exclusion
criteria exist at screening, or at the timepoint specified in the individual criterion
listed:

1. Unable or unwilling to provide informed consent. (Subjects must provide separate
informed consent for this study.)

2. A MS relapse, as determined by the Investigator, which occurred within 90 days
prior to screening, or the subject has not stabilized from a previous relapse
prior to screening.

3. Any contraindication to having a brain magnetic resonance imaging (MRI) (e.g.,
pacemaker, MRI-incompatible aneurysm clips, artificial heart valves, or other
metal foreign body; claustrophobia that cannot be medically managed) or
contraindication for administration of gadolinium-contrast agent.

4. Clinically significant brain MRI finding other than those related to MS, as
judged by the Investigator, at screening.

5. Any contraindications to having a LP (e.g., aspirin greater than 325 mg/day,
warfarin, clopidrogel, decreased platelet count, prolonged PT or PTT more than 1
½ over normal) as determined by history and Investigator decision.

6. Evidence of history of autoimmune disease (e.g., rheumatoid arthritis, systemic
lupus erythematosus, ulcerative colitis, diabetes mellitus) with the exception of
MS.

7. Any sign of chronic active infection, requiring antibiotic treatment (refer to
Exclusion 23) (e.g., urinary tract infection, bronchitis, hepatitis, and
tuberculosis) except for those requiring topical medication for treatment (e.g.,
athletes foot), or screening laboratory evidence consistent with a significant
chronic active acute infection requiring systemic treatment.

8. Pregnant; or breastfeeding females; or males of fathering potential or females of
childbearing potential who are unwilling or unable to use an effective method of
contraception as outlined in this protocol (Section 12.5) for the duration of the
study and for at least 28 days after the last dose of DMF use in this protocol.
For females of childbearing potential, a positive pregnancy test at any time
within the protocol.

9. Known positive human immunodeficiency virus antibody, hepatitis B surface
antigen, hepatitis B core antibody, or hepatitis C antibody tests indicative of
present or prior infection.

10. Any abnormal hematology values or clinical chemistry values judged by the
Investigator or Sponsor as clinically significant, including white blood cell
count (WBC) 3500/mm3, or absolute lymphocyte count lower limit of normal.

11. Positive Quantiferon-Tuberculosis Gold In-Tube test (QFT-GIT) at screening or
known history of active tuberculosis not adequately treated.

12. Any malignancy within 5 years, except for basal or squamous cell skin lesions
which have been surgically excised, with no evidence of metastasis.

13. Any clinical, CSF, or MRI evidence for progressive multifocal
leukoencephalopathy, from historical MRI.

14. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or that may interfere with the
interpretation of study results and, in the judgment of the Investigator, would
make the subject inappropriate for entry into this study.

15. Subjects participating in or expecting to participate in other interventional
clinical trials, except those participating in Study US-BGT-US-10766 at the same
site.

16. History of drug or alcohol abuse (as defined by the Investigator) within 2 years
prior to screening.

Exclusion Criteria Related to Medication

17. Previous exposure to DMF for disease management at any time in the past.

18. History of severe allergic or anaphylactic reactions or known drug
hypersensitivity to fumaric acid or fumaric acid esters.

19. Treatment with methylprednisolone or other systemic corticosteroid for MS relapse
or otherwise within 30 days prior to Day 1 of study treatment.

20. Treatment with MS disease modifying therapies as follows:

Beta interferons (interferon beta-1a [Avonex® or Rebif®] or interferon beta-1b
[Betaseron®], or glatiramer acetate [Copaxone®] within 6 weeks prior to Baseline.

Fingolimod (Gilenya®), teriflunomide (Aubagio®) within 6 months prior to
Baseline, except teriflunomide washout with accelerated elimination and
verification of zero serum levels of teriflunomide prior Baseline.

Natalizumab (Tysabri®) within 6 months prior to Screening OR 1 month prior to
screening if subject has a positive Nabs (neutralizing antibodies) to Tysabri®
Treatment within the past 5 years or current treatment with any of the following
agents: cyclosporine, cladribine, agents that are immunosuppressive (e.g.,
entanercept), murine protein, T-cell vaccination), or stem cell transplantation
prior to Screening.

Treatment within the past 2 years with rituximab, IVIG, or mycophenolate

21. Receipt of any non-live vaccine within the previous 14 days or live vaccine
within 30 days prior to first dose of study treatment.

22. Treatment with an investigational drug within 30 days or 5 half-lives preceding
the first dose of study treatment, whichever is longer.

23. Use of antibiotics for any reason within 3 months of Screening. Inclusion



Age minimum: 25 Years
Age maximum: 65 Years
Gender: All
Health Condition(s) or Problem(s) studied
Multiple Sclerosis
Intervention(s)
Drug: BG00012 (DMF) (Tecfidera®.)
Primary Outcome(s)
The primary objective of the study is to investigate the PK (drug level) of MMF( the primary metabolite of study drug) in plasma in subjects with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of DMF conjugate (study drug) in plasma in subjects with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of DMF(study drug) in CSF with SPMS. [Time Frame: post-DMF treatment in Week 6]
The primary objective of the study is to investigate the PK (drug level) of MMF (the primary metabolite of study drug) conjugate in CSF with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of DMF conjugate (study drug) in CSF with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of DMF(study drug) in plasma in subjects with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of MMF( the primary metabolite of study drug) conjugate in plasma in subjects with SPMS. [Time Frame: treatment in week 6]
The primary objective of the study is to investigate the PK (drug level) of MMF(the primary metabolite of study drug) in CSF with SPMS. [Time Frame: treatment in week 6]
Secondary Outcome(s)
A secondary objective is to assess the effects of DMF on pharmacogenomic biomarkers in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on RNA samples from CSF cellular pellet for transcriptionomics in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on biomarkers of oxidative stress in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on biomarkers of neuroaxonal damage in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on biomarkers of inflammation in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on myelin lipid biomarkers in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
A secondary objective is to assess the effects of DMF on PD biomarkers downstream of Nrf2 in the CSF of subjects with SPMS. [Time Frame: at 28 weeks]
Secondary ID(s)
BG12-001
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Biogen
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history